In the Kidney Inner Medulla (Prostaglandin E2/Collecting Duct) T

Total Page:16

File Type:pdf, Size:1020Kb

In the Kidney Inner Medulla (Prostaglandin E2/Collecting Duct) T Proc. Nati. Acad. Sci. USA Vol. 88, pp. 3170-3174, April 1991 Physiology/Pharmacology Characterization of a dopamine receptor (DA2K) in the kidney inner medulla (prostaglandin E2/collecting duct) T. Huo, M. Q. YE, AND D. P. HEALY* Department of Pharmacology, Mount Sinai School of Medicine of the City University of New York, New York, NY 10029 Communicated by Karl H. Beyer, Jr., December 18, 1990 (received for review September 17, 1990) ABSTRACT Dopamine (DA) produces a natriuretic/diuretic branes (14-17), although the precise localization of the bind- response in the kidney by mcnisms that are still not well ing sites remains unclear. understood. There is some ination that DA2 receptors may be Therefore, to gain further insight into the possible role of involved in mating the effects ofDA, but little is known regard- DA2 receptors in the kidney, we sought to localize the DA2 ing the nature of this receptor in the kidney. Autoraigaphic receptor by in vitro autoradiography with [3H]spiperone and localation of [3Hspiperone, a DA2 anta t, i ed that then to characterize the receptor pharmacologically, bio- high-density binding was r ic to inner meduilary ting chemically, and physiologically. ducts (IMCDs). [3H]Spiperoe binding was saturable, high affinity (Kd, 17.2 ± 1.65 aM), and high density (Bmq, 935 ± 83 fnol per MATERIALS AND METHODS mg ofprotein). The photosensitive spiperone anogeNp-azido- m-['25j]iodophenethyl)sIperone labeled similr sized proteins of In Vitro Autoradiography. In vitro autoradiography of M - 120,000 in membranes prepared from the kidney inner [3H]spiperone was conducted by a procedure similar to that medulla, sum, and pituitary. However, the rank-order com- described in ref. 11. Male Sprague-Dawley rats (200-250 g; petition profile for the [3llspiperone binding in the kidney inner Charles River Breeding Laboratories) were anesthetized with medulla differed from the DA2 receptor in striatum and pituitary sodium pentobarbital (50 mg/kg; i.p.) and perfused transcar- and, furthrinore, RNA (Northern) blot analyses of kidney inner dially with 200 ml of 0.1% formalin in phosphate-buffered medullary RNA with brain DA2 receptor oligonuleotide probes saline, and the kidneys were excised. Slide-mounted 15-,um were negative. Functionally, DA stimulated pI E2 pro cryostat sections of kidney were incubated with 10 nM duction by IMCD cells, an effect that could be blocked by the DA2 [3H]spiperone (specific activity 75-85 Ci/mmol; 1 Ci = 37 antagonist domperidone. These results indicate that the kidney GBq; Amersham) in 50 mM Tris buffer (pH 7.4) containing inner medulla expresses a functional DA receptor that may rep- 120 mM NaCl, 5 mM KCI, 2 mM CaC12, 1 mM MgCl2, 100 AM resent a newly identified DA receptor subtype (here d pargyline, and 0.1% ascorbic acid for 60 min at room tem- DAmK). Moreover, these rels suggest that the kidney inner perature, rinsed twice for 30 min each in fresh buffer at 40C, medulla may be a s f t site at which DA, either directly or dried, and exposed to Hyperfilm (Amersham) for 2 weeks. indirectly, influences water and electrolyte excretion. Nonspecific binding was determined in the presence of 100 ,M haloperidol. Exogenous dopamine (DA) produces a natriuretic/diuretic re- Homogenate Binding. Crude membranes from the kidney sponse in a variety of species, including humans (1, 2). The inner medulla were prepared as described for kidney cortex natriuretic effects of DA are generally thought to be due to an (11). Assays were conducted by incubating 50 ,ug of crude increase in renal blood flow and glomerular filtration rate (1) but membrane protein at 250C for 30 min in incubation buffer, as may include direct tubular effects since low doses of DA described above, containing dilute radioligand and drug or increase urine output and urinary sodium excretion without vehicle, followed by vacuum filtration through Whatman altering renal hemodynamics (3-5). Although the mechanism of GF/C filters. For saturation binding experiments, 1-100 nM action ofDA within the kidney is not resolved, the effects ofDA [3H]spiperone was used. Nonspecific binding was defined as on the kidney are blocked by DA receptor antagonists (2, 6, 7). binding in the presence of 100 ,uM haloperidol, with a DA receptors have been classified in the central nervous system total/nonspecific binding ratio of =4:1. For competition as D1 and D2 (8) and in the periphery as DA1 and DA2 (9). A studies, 5 nM [3H]spiperone was used together with increas- great deal of evidence indicates that vascular and tubular DA1 ing concentrations ofunlabeled DA agonists and antagonists. receptors are involved in mediating the actions of DA on the Photoaffinity Labeling. Photoaffinity cross-linking with kidney (6, 7). Further support for a tubular site ofaction for DA N-(p-azido-m-[251I]iodophenethyl)spiperone ([125I]N3-NAPS) comes from autoradiographic localization of DA1 receptors in was conducted similar to the procedure ofAmlaiky and Caron rat kidney, which indicates that the highest levels are found in (18) and Senogles et al. (19) with only minor modifications. In the proximal tubules (10, 11). particular, membranes from the striatum, pituitary, and kid- Much less is known regarding the role of DA2 receptors in ney inner medulla were prepared in 25 mM Tris-HCl, pH 7.2 mediating the renal responses to DA. Spiperone, a central (250C)/250 mM sucrose containing the following protease nervous system D2 antagonist, blocks the DA-stimulated inhibitors: 10 mM EDTA, 10 mM EGTA, benzamidine (15 increase in renal blood flow and sodium excretion in isolated Ag/ml), soybean trypsin inhibitor (5 jg/ml), leupeptin (5 perfused rat kidney (4). Bromocriptine, a DA2 agonist, has Ag/ml), 1 mM phenylmethylsulfonyl fluoride, pepstatin (100 been reported to increase renal blood flow and single- nephron glomerular filtration rate in the rat (12, 13). [3H]Spip- Abbreviations: DA, dopamine; [1251]N3-NAPS, N-(p-azido-m- erone binding has been reported in kidney cortical mem- [125I]iodophenethyl)spiperone; IMCD, inner medullary collecting duct; PGE2, prostaglandin E2; 6,7-ADTN, 6,7-dihydroxy-1,2,3,4- tetrahydronaphthalene; 5-HT2, 5-hydroxytryptamine 2. The publication costs of this article were defrayed in part by page charge *To whom reprint requests should be addressed at: Department of payment. This article must therefore be hereby marked "advertisement" Pharmacology, Box 1215, Mount Sinai School of Medicine, One in accordance with 18 U.S.C. §1734 solely to indicate this fact. Gustave L. Levy Place, New York, NY 10029. 3170 Downloaded by guest on September 28, 2021 Physiology/Pharmacology: Huo et al. Proc. Natl. Acad. Sci. USA 88 (1991) 3171 ng/ml), aprotinin (5 ,ug/ml), 1 mM phenanthroline. Mem- were synthesized and labeled to high specific activity with branes (100-300 jig of protein for all three tissues) were [y-32P]ATP and T4 polynucleotide kinase. incubated in the dark with [1251]N3-NAPS (0.1-0.25 nM for Inner Medullary Collecting Duct (IMCD) Cell Isolation and striatum and pituitary and 0.25-0.5 nM for kidney inner Culture. IMCD cells were isolated from renal inner medulla medulla) for 60 min at room temperature. The membranes ofSprague-Dawley rats (200-250 g) according to the methods were then washed as described above and resuspended in of Sato and Dunn (22) and are described in detail elsewhere buffer. (T.H. and D.P.H., unpublished data). Cells were maintained incubation Photolysis was performed by exposing the 1 day in Dulbecco's modified Eagle's medium/F-12 medium incubation mixtures for 90 s at 12 cm from a high-pressure supplemented with 10% fetal calf serum and then changed to mercury lamp. The membranes were pelleted and resus- a fully defined K-1 medium. pended in SDS/PAGE sample buffer [50 mM Tris HCl, pH Prostaglandin E2 (PGE2) Production. IMCD cells were 6.8/10% SDS/10% (vol/vol) glycerol/5% 2-mercaptoethanol/ maintained in 24-well culture dishes and incubated in tripli- 0.003% bromophenol blue] containing protease inhibitors and cate for 60 min with medium containing 100 ,AM pargyline, were electrophoresed on a discontinuous SDS/10%o polyacryl- 0.01% ascorbic acid, and the appropriate drugs, and the amide gel. An equivalent amount of protein was loaded onto medium was assayed for PGE2 content by radioimmunoas- each lane. After electrophoresis, the gels were dried and say. Values were expressed as means ± SEM of triplicate exposed to autoradiographic film. culture wells based on experiments repeated 3-12 times. RNA (Northern) Blot Analysis. Total cellular-RNA was iso- Pharmacological Agents. The following drugs were used: lated from fresh rat tissues according to the method of Chom- LY171555 (Lilly Research Laboratories); ketanserin (Janssen czynski and Sacchi (20). Twenty micrograms oftotal RNA from Pharmaceutica); SKF 83566 and SKF 38393 (Smith Kline & each tissue was fractionated by electrophoresis on a 1% agarose French); cis(Z)-flupentixol (H. Lundbech A/S, Copenhagen); formaldehyde gel, transferred to nitrocellulose membranes, I-sulpride and d-sulpride (Ravizza, Milan); Sch 23390 (Scher- hybridized overnight with the 32P-labeled oligonucleotide probe ring); spiperone, 6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene at 590C, and washed the following day three times for 30 min (6,7-ADTN), (+)- and (-)-butaclamol, Sch 23388, and pargyline each in 3 x NET (lx NET = 150 mM NaCI/1 mM EDTA/15 (Research Biochemicals, Natick, MA). mM Tris HCI, pH 8) at 55°C. The nitrocellulose paper was then dried and exposed 2 days at -80°C with intensifying screens. RESULTS Two synthetic oligonucleotide probes complementary to the rat Autoradiographic localization of [3H]spiperone binding sites striatal D2 receptor mRNA at bases 478-522 and 1213-1254 (21) indicated that binding was concentrated in the inner medulla I .M' FIG.
Recommended publications
  • Dopamine: a Role in the Pathogenesis and Treatment of Hypertension
    Journal of Human Hypertension (2000) 14, Suppl 1, S47–S50 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh Dopamine: a role in the pathogenesis and treatment of hypertension MB Murphy Department of Pharmacology and Therapeutics, National University of Ireland, Cork, Ireland The catecholamine dopamine (DA), activates two dis- (largely nausea and orthostasis) have precluded wide tinct classes of DA-specific receptors in the cardio- use of D2 agonists. In contrast, the D1 selective agonist vascular system and kidney—each capable of influenc- fenoldopam has been licensed for the parenteral treat- ing systemic blood pressure. D1 receptors on vascular ment of severe hypertension. Apart from inducing sys- smooth muscle cells mediate vasodilation, while on temic vasodilation it induces a diuresis and natriuresis, renal tubular cells they modulate sodium excretion. D2 enhanced renal blood flow, and a small increment in receptors on pre-synaptic nerve terminals influence nor- glomerular filtration rate. Evidence is emerging that adrenaline release and, consequently, heart rate and abnormalities in DA production, or in signal transduc- vascular resistance. Activation of both, by low dose DA tion of the D1 receptor in renal proximal tubules, may lowers blood pressure. While DA also binds to alpha- result in salt retention and high blood pressure in some and beta-adrenoceptors, selective agonists at both DA humans and in several animal models of hypertension. receptor classes have been studied in the treatment of
    [Show full text]
  • Steven, Stacy (2012) the Pharmacology of the 5-HT2A Receptor and the Difficulty Surrounding Single Taret Models
    Steven, Stacy (2012) The pharmacology of the 5-HT2A receptor and the difficulty surrounding single taret models. MSc(R) thesis. http://theses.gla.ac.uk/3636/ Copyright and moral rights for this thesis are retained by the author A copy can be downloaded for personal non-commercial research or study, without prior permission or charge This thesis cannot be reproduced or quoted extensively from without first obtaining permission in writing from the Author The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the Author When referring to this work, full bibliographic details including the author, title, awarding institution and date of the thesis must be given Glasgow Theses Service http://theses.gla.ac.uk/ [email protected] The pharmacology of the 5-HT2A receptor and the difficulty surrounding functional studies with single target models A thesis presented for the degree of Master of Science by research Stacy Steven April 2012 Treatment of many disorders can be frequently problematic due to the relatively non selective nature of many drugs available on the market. Symptoms can be complex and expansive, often leading to symptoms representing other disorders in addition to the primary reason for treatment. In particular mental health disorders fall prey to this situation. Targeting treatment can be difficult due to the implication of receptors in more than one disorder, and more than one receptor in a single disorder. In the instance of GPCRs, receptors such as the serotonin receptors (and in particular the 5-HT2A for the interest of this research) belong to a large family of receptors, the GPCR Class A super family.
    [Show full text]
  • Selective Labeling of Serotonin Receptors Byd-[3H]Lysergic Acid
    Proc. Nati. Acad. Sci. USA Vol. 75, No. 12, pp. 5783-5787, December 1978 Biochemistry Selective labeling of serotonin receptors by d-[3H]lysergic acid diethylamide in calf caudate (ergots/hallucinogens/tryptamines/norepinephrine/dopamine) PATRICIA M. WHITAKER AND PHILIP SEEMAN* Department of Pharmacology, University of Toronto, Toronto, Canada M5S 1A8 Communicated by Philip Siekevltz, August 18,1978 ABSTRACT Since it was known that d-lysergic acid di- The objective in this present study was to improve the se- ethylamide (LSD) affected catecholaminergic as well as sero- lectivity of [3H]LSD for serotonin receptors, concomitantly toninergic neurons, the objective in this study was to enhance using other drugs to block a-adrenergic and dopamine receptors the selectivity of [3HJISD binding to serotonin receptors in vitro by using crude homogenates of calf caudate. In the presence of (cf. refs. 36-38). We then compared the potencies of various a combination of 50 nM each of phentolamine (adde to pre- drugs on this selective [3H]LSD binding and compared these clude the binding of [3HJLSD to a-adrenoceptors), apmo ie, data to those for the high-affinity binding of [3H]serotonin and spiperone (added to preclude the binding of [3H[LSD to (39). dopamine receptors), it was found by Scatchard analysis that the total number of 3H sites went down to 300 fmol/mg, compared to 1100 fmol/mg in the absence of the catechol- METHODS amine-blocking drugs. The IC50 values (concentrations to inhibit Preparation of Membranes. Calf brains were obtained fresh binding by 50%) for various drugs were tested on the binding of [3HLSD in the presence of 50 nM each of apomorphine (A), from the Canada Packers Hunisett plant (Toronto).
    [Show full text]
  • Identification Ofa D1 Dopamine Receptor, Not Linked To
    Br. J. Pharmacol. (1991), 103, 1928-1934 11--" Macmillan Press Ltd, 1991 Identification of a D1 dopamine receptor, not linked to adenylate cyclase, on lactotroph cells 'Danny F. Schoors, *Georges P. Vauquelin, *Hilde De Vos, fGerda Smets, Brigitte Velkeniers, Luc Vanhaelst & Alain G. Dupont Department of Pharmacology, Medical School, Vrije Universiteit Brussel (V.U.B.), Laarbeeklaan 103, B-1090, Brussels, Belgium; *Protein Chemistry Laboratory, Instituut voor Moleculaire Biologie, V.U.B., Paardenstraat 65, St-Genesius-Rode, Belgium and tDepartment of Experimental Pathology, Medical School, V.U.B., Laarbeeklaan 103, B-1090, Brussels, Belgium 1 We studied the lactotroph cells of the rat by both in vivo and in vitro pharmacological techniques for the presence of D1-receptors. Both approaches revealed the presence of a D2-receptor, stimulated by quinpirole (resulting in an inhibition of prolactin secretion) and blocked by domperidone. 2 Administration of fenoldopam, the most selective Dl-receptor agonist currently available, resulted in a dose-dependent decrease of prolactin secretion in vivo (after pretreatment with a-methyl-p-tyrosine) and in vitro (cultured pituitary cells). This increase was dose-dependently blocked by the selective D1-receptor antagonist, SCH 23390, and although the effect of fenoldopam was less than that obtained by D2-receptor stimulation, these data suggest that a D,-receptor also controls prolactin secretion. 3 In order to detect the location of these dopamine receptors, autoradiographic studies were performed by use of [3H]-SCH 23390 and [3H]-spiperone as markers for D1- and D2-receptors, respectively. Specific binding sites for [3H]-SCH 23390 were demonstrated. Fenoldopam dose-dependently reduced [3H]-SCH 23390 binding, but had no effect on [3H]-spiperone binding.
    [Show full text]
  • Antipsychotics (Part-4) FLUOROBUTYROPHENONES
    Antipsychotics (Part-4) FLUOROBUTYROPHENONES The fluorobutyrophenones belong to a much-studied class of compounds, with many compounds possessing high antipsychotic activity. They were obtained by structure variation of the analgesic drug meperidine by substitution of the N-methyl by butyrophenone moiety to produce the butyrophenone analogue which has similar activity as chlorpromazine. COOC2H5 N H3C Meperidine COOC2H5 N O Butyrophenone analog The structural requirements for antipsychotic activity in the group are well worked out. General features are expressed in the following structure. F AR Y O N • Optimal activity is seen when with an aromatic with p-fluoro substituent • When CO is attached with p-fluoroaryl gives optimal activity is seen, although other groups, C(H)OH and aryl, also give good activity. • When 3 carbons distance separates the CO from cyclic N gives optimal activity. • The aliphatic amino nitrogen is required, and highest activity is seen when it is incorporated into a cyclic form. • AR is an aromatic ring and is needed. It should be attached directly to the 4-position or occasionally separated from it by one intervening atom. • The Y group can vary and assist activity. An example is the hydroxyl group of haloperidol. The empirical SARs suggest that the 4-aryl piperidino moiety is superimposable on the 2-- phenylethylamino moiety of dopamine and, accordingly, could promote affinity for D2 receptors. The long N-alkyl substituent could help promote affinity and produce antagonistic activity. Some members of the class are extremely potent antipsychotic agents and D2 receptor antagonists. The EPS are extremely marked in some members of this class, which may, in part, be due to a potent DA block in the striatum and almost no compensatory striatal anticholinergic block.
    [Show full text]
  • Additions and Deletions to the Drug Product List
    Prescription and Over-the-Counter Drug Product List 36TH EDITION Cumulative Supplement Number 10 : October 2016 ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST ABACAVIR SULFATE TABLET;ORAL ABACAVIR SULFATE >A> AB STRIDES ARCOLAB LTD EQ 300MG BASE A 091050 001 Oct 28, 2016 Oct NEWA ACETAMINOPHEN; BUTALBITAL TABLET;ORAL BUTALBITAL AND ACETAMINOPHEN >A> AA MIKART INC 300MG;50MG A 207386 001 Nov 15, 2016 Oct NEWA >D> + NEXGEN PHARMA 300MG;50MG A 090956 001 Aug 23, 2011 Oct CTEC >A> AA + 300MG;50MG A 090956 001 Aug 23, 2011 Oct CTEC ACETAMINOPHEN; BUTALBITAL; CAFFEINE CAPSULE;ORAL BUTALBITAL, ACETAMINOPHEN AND CAFFEINE >D> + NEXGEN PHARMA 300MG;50MG;40MG A 040885 001 Nov 16, 2009 Oct CFTG >A> AB + 300MG;50MG;40MG A 040885 001 Nov 16, 2009 Oct CFTG >A> AB NUVO PHARM INC 300MG;50MG;40MG A 207118 001 Oct 28, 2016 Oct NEWA ACETAZOLAMIDE TABLET;ORAL ACETAZOLAMIDE >A> AB HERITAGE PHARMA 125MG A 205530 001 Oct 27, 2016 Oct NEWA >A> AB 250MG A 205530 002 Oct 27, 2016 Oct NEWA ALBUTEROL SULFATE TABLET;ORAL ALBUTEROL SULFATE >A> @ DAVA PHARMS INC EQ 2MG BASE A 072860 002 Dec 20, 1989 Oct CMS1 ALENDRONATE SODIUM TABLET;ORAL ALENDRONATE SODIUM >D> @ SANDOZ EQ 5MG BASE A 075871 001 Apr 22, 2009 Oct CAHN >D> @ EQ 10MG BASE A 075871 002 Apr 22, 2009 Oct CAHN >D> @ EQ 35MG BASE A 075871 004 Apr 22, 2009 Oct CAHN >D> @ EQ 40MG BASE A 075871 003 Apr 22, 2009 Oct CAHN >D> @ EQ 70MG BASE A 075871 005 Apr 22, 2009 Oct CAHN >A> @ UPSHER-SMITH LABS EQ 5MG BASE A 075871 001 Apr 22, 2009 Oct CAHN >A> @ EQ 10MG BASE A 075871 002 Apr 22, 2009 Oct CAHN >A> @ EQ
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • Volume 19 • Number 3 • 2002
    CONTROLLED RELEASE SOCIETY Volume 19 • Number 32 • 2002 NEWSLETTER CRS Updates Entrepeneuer Scientific Tomorrow’s Passing theGavel Passing Spotlight: ALZA www.controlledrelease.org We characterize macromolecules from eighteen different angles. So you don’t have to. Eighteen angles may sound like a lot. But it’s not when Wyatt instruments have helped thousands of scientists, you consider that molecular weights and sizes can’t be from Nobel laureates to members of the National Academy determined accurately from one or two angles. of Sciences to researchers in over 50 countries worldwide. That’s why Wyatt’s multi-angle light scattering systems We also provide unmatched training, service, and deploy the greatest number of detectors over the support, as well as ongoing access to our nine PhD broadest range of angles. In fact, a Wyatt DAWN® scientists with broad expertise in liquid chromatography, instrument directly measures molecular weights polymer chemistry, protein science, biochemistry, and sizes without column calibration or and light scattering. reference standards —with up to 25 times For more information on our more precision than one or full range of instruments, worldwide dealer two angle instruments.* network, applications, and a bibliography No wonder 28 of the of light scattering papers, please call top 30 chemical, pharmaceutical, 805-681-9009, fax us at 805-681-0123, or visit us at and biotechnology companies rely on www.wyatt.com. We’ll show Wyatt instruments, as do all major fed- you how to generate data eral regulatory agencies and national laboratories. so precise, you won’t believe CORPORATION your eyes. *Precision improvement from measuring with Wyatt Multi-Angle Light scattering detectors vs.
    [Show full text]
  • Pharmacology Review(S)
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 200603 PHARMACOLOGY REVIEW(S) Tertiary Pharmacology/Toxicology Review From: Paul C. Brown, Ph.D., ODE Associate Director for Pharmacology and Toxicology, OND IO NDA: 200603 Agency receipt date: 12/30/2009 Drug: Lurasidone hydrochloride Applicant: Sunovion Pharmaceuticals (Originally submitted by Dainippon Sumimoto Pharma America, Inc.) Indication: schizophrenia Reviewing Division: Division of Psychiatry Products Background: The pharm/tox reviewer and team leader concluded that the nonclinical data support approval of lurasidone for the indication listed above. Reproductive and Developmental Toxicity: Reproductive and developmental toxicity studies in rats and rabbits revealed no evidence of teratogenicity or embryofetal toxicity. The high doses in the rat and rabbit embryofetal toxicity studies were 3 and 12 times, respectively, the maximum recommended human dose (80 mg) based on a body surface area comparison. Carcinogenicity: Lurasidone was tested in 2 year rat and mouse carcinogenicity studies. These studies were reviewed by the division and the executive carcinogenicity assessment committee. The committee concluded that the studies were adequate and that there was a drug-related increase in mammary carcinomas in female rats at doses of 12 mg/kg and higher and a drug-related increase in mammary carcinomas and adenoacanthomas and pituitary pars distalis adenomas in female mice. The applicant also provided data from various studies showing that lurasidone significantly increases prolactin in several different species including rats and mice. Conclusions: I agree with the division pharm/tox conclusion that this application can be approved from a pharm/tox perspective. The division recommends that lurasidone be labeled with pregnancy category B.
    [Show full text]
  • National Drug List
    National Drug List Drug list — Five Tier Drug Plan Your prescription benefit comes with a drug list, which is also called a formulary. This list is made up of brand-name and generic prescription drugs approved by the U.S. Food & Drug Administration (FDA). The following is a list of plan names to which this formulary may apply. Additional plans may be applicable. If you are a current Anthem member with questions about your pharmacy benefits, we're here to help. Just call us at the Pharmacy Member Services number on your ID card. Solution PPO 1500/15/20 $5/$15/$50/$65/30% to $250 after deductible Solution PPO 2000/20/20 $5/$20/$30/$50/30% to $250 Solution PPO 2500/25/20 $5/$20/$40/$60/30% to $250 Solution PPO 3500/30/30 $5/$20/$40/$60/30% to $250 Rx ded $150 Solution PPO 4500/30/30 $5/$20/$40/$75/30% to $250 Solution PPO 5500/30/30 $5/$20/$40/$75/30% to $250 Rx ded $250 $5/$15/$25/$45/30% to $250 $5/$20/$50/$65/30% to $250 Rx ded $500 $5/$15/$30/$50/30% to $250 $5/$20/$50/$70/30% to $250 $5/$15/$40/$60/30% to $250 $5/$20/$50/$70/30% to $250 after deductible Here are a few things to remember: o You can view and search our current drug lists when you visit anthem.com/ca and choose Prescription Benefits. Please note: The formulary is subject to change and all previous versions of the formulary are no longer in effect.
    [Show full text]
  • Haloperidol Metabolites Elisa Kit Instructions Product #102119 & 102116 Forensic Use Only
    Neogen Corporation 944 Nandino Blvd., Lexington KY 40511 USA 800/477-8201 USA/Canada | 859/254-1221 Fax: 859/255-5532 | E-mail: [email protected] | Web: www.neogen.com/Toxicology HALOPERIDOL METABOLITES ELISA KIT INSTRUCTIONS PRODUCT #102119 & 102116 FORENSIC USE ONLY INTENDED USE: For the determination of trace quantities of Haloperidol Metabolites in human urine, blood, oral fluid. DESCRIPTION Neogen Corporation’s Haloperidol Metabolites ELISA (Enzyme-Linked ImmunoSorbent Assay) test kit is a qualitative one- step kit designed for use as a screening device for the detection of drugs and/or their metabolites. The kit was designed for screening purposes and is intended for forensic use only. It is recommended that all suspect samples be confirmed by a quantitative method such as gas chromatography/mass spectrometry (GC/MS). ASSAY PRINCIPLES Neogen Corporation’s test kit operates on the basis of competition between the drug or its metabolite in the sample and the drug-enzyme conjugate for a limited number of antibody binding sites. First, the sample or control is added to the microplate. Next, the diluted drug-enzyme conjugate is added and the mixture is incubated at room temperature. During this incubation, the drug in the sample or the drug-enzyme conjugate binds to antibody immobilized in the microplate wells. After incubation, the plate is washed 3 times to remove any unbound sample or drug-enzyme conjugate. The presence of bound drug-enzyme conjugate is recognized by the addition of K-Blue® Substrate (TMB). After a 30 minute substrate incubation, the reaction is halted with the addition of Red Stop Solution.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20060166972A1 (19) United States (12) Patent Application Publication (10) Pub. N0.2 US 2006/0166972 A1 Conn et al. (43) Pub. Date: Jul. 27, 2006 (54) TREATMENT OF MOVEMENT DISORDERS Publication Classi?cation WITH A METABOTROPIC GLUTAMATE 4 RECEPTOR POSITIVE ALLOSTERIC (51) Int. Cl. MODULATOR A611; 31/5513 (2006.01) A611; 31/551 (2006.01) (76) Inventors: P. Je?rey Conn, BrentWood, TN (US); A611; 31/5415 (2006.01) Anthony G DiLella, Lansdale, PA A611; 31/553 (2006.01) (US); Gene G Kinney, Collegeville, PA A611; 31/198 (2006.01) (US); Michael J Marino, Souderton, A611; 31/445 (2006.01) PA (US); Guy R Seabrook, Blue Bell, A611; 31/48 (2006.01) PA (US); David L Williams, Telford, (52) US. Cl. .................... ..514/220;514/221;514/2258; PA (US) 514/284; 514/317; 514/567; 514/649 Correspondence Address: MERCK AND CO., INC (57) ABSTRACT P 0 BOX 2000 RAHWAY, NJ 07065-0907 (US) An mGluR4 receptor positive allosteric modulator is useful, (21) App1.No.: 10/564,029 alone or in combination With a neuroleptic agent, for treating or preventing movement disorders such as Parkinson’s dis (22) PCT Filed: Jul. 7, 2004 ease, dyskinesia, tardive dyskinesia, drug-induced parkin sonism, postencephalitic parkinsonism, progressive supra (86) PCT No.: PCT/US04/21776 nuclear palsy, multiple system atrophy, corticobasal degeneration, parkinsonian-ALS dementia complex, basal Related US. Application Data ganglia calci?cation, akinesia, akinetic-rigid syndrome, bradykinesia, dystonia, medication-induced parkinsonian, (60) Provisional application No. 60/486,691, ?led on Jul. Gilles de la Tourette syndrome, Huntington’s disease, 11, 2003.
    [Show full text]